

AMENDMENTS TO THE CLAIMS

1-48. (canceled)

49. (currently amended): An isolated or recombinant polypeptide ~~[[ef]]~~ having SEQ ID NO: 3, 5, or 7 ~~12 or encoded by a nucleotide sequence of SEQ ID NO: 2, 4, or 6 or fragment or variant thereof wherein the fragment or variant induces a specific antibody response.~~

50-53. (canceled)

54. (currently amended): ~~[[The]]~~ A fragment of a polypeptide of claim 49 consisting of at least nine, ten, or fifteen contiguous amino acids of the polypeptide, wherein the fragment induces a specific antibody response.

55. (currently amended): ~~The polypeptide of claim 49~~ fragment of claim 54 comprising one or more immunoreactive epitope(s).

56. (currently amended): ~~The polypeptide fragment of claim 54 comprising~~ consisting of the polypeptide of any of Tables VIII to XLIX.

57. (currently amended): ~~An immunogenic~~ A composition which comprises the polypeptide of claim 49 in admixture with at least one and a pharmaceutically acceptable excipient carrier.

58. (currently amended): A method of generating an immune response in a mammalian subject comprising exposing cells of the mammal's immune system ~~to an amount of the a polypeptide of claim 49 sufficient to generate said~~ having SEQ ID NO: 3, 5, or 7, whereby an immune response to the polypeptide is generated.

59. (previously presented): The method of claim 58 wherein the polypeptide has at least one T cell or at least one B cell epitope.

60. (currently amended): The method of ~~claim 59~~ claim 58 wherein the immune response comprises ~~an individual~~ activation of a B cell that generates antibodies that specifically bind to the polypeptide.

61. (currently amended): The method of ~~claim 60~~ claim 58 wherein the immune response comprises activating a T cell that is a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the polypeptide.

62. (currently amended): The method of ~~claim 60~~ claim 58 wherein the immune response comprises activating ~~a T cell that is~~ a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody-producing activity of a B cell.

63. (previously presented): A polynucleotide that encodes the polypeptide of claim 49 or is fully complementary to the polynucleotide wherein T can also be U.

64-65. (canceled)

66. (currently amended): The polynucleotide of claim 63 having SEQ ID NO: 2, 4, or 6, ~~or a nucleotide sequence encoding SEQ ID NO: 3, 5, or 7-12.~~

67-71. (canceled)

72. (currently amended): An isolated host cell modified to contain an expression vector for expressing the polynucleotide of claim 63 ~~and capable of producing a polypeptide encoded by the polynucleotide.~~

73-74. (canceled)

75. (currently amended): A method for ~~monitoring expression levels of a polypeptide of claim 49 or mRNA which encodes said polynucleotide in a biological sample from a subject who~~

~~has or is suspected of having~~ detecting the presence of cancer versus a normal sample in an individual comprising:

~~determining the level of [[the]] expression of a polypeptide or mRNA expressed by cells in a biological sample from the subject~~ having SEQ ID NO: 3, 5, or 7 in a test sample from an individual; and

~~determining~~ comparing the level so determined to the level of expression that is evidenced in a ~~of the polypeptide or mRNA expressed by cells in a corresponding normal sample,~~

wherein the elevated expression of said polypeptide in the test sample versus the ; and

~~comparing the levels of the polypeptide or mRNA determined in the biological sample to the level of the polypeptide or mRNA determined in the corresponding normal sample~~ is an indication of the presence of cancer.

76. (canceled)

77. (currently amended): The method of ~~claim 76~~ claim 75 wherein the cancer ~~occurs in a tissue which is lung or~~ is selected from the group of cancers consisting of lung, ovary, breast pancreas, and prostate.

78. (canceled)

79. (new): The method of claim 58, wherein the polypeptide is expressed in a viral vector.

80. (new): The method of claim 79 wherein the viral vector is selected from the group consisting of vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and Sindbis virus.